Brainstorm Cell Therapeutics Inc. (BCLI) financial statements (2022 and earlier)

Company profile

Business Address 1325 AVENUE OF AMERICAS
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22,09441,9365697,0647,7569,990
Cash and cash equivalents18,85637,8295369422,483547
Short-term investments3,2384,107336,1225,2739,443
Receivables863042,3592,009672306
Prepaid expense  2761,1031,103 
Other undisclosed current assets1,1001,0021569492148
Total current assets:23,28043,2423,36010,2709,62310,444
Noncurrent Assets
Other noncurrent assets5,9978,0173,1749581,800322
Total noncurrent assets:5,9978,0173,1749581,800322
TOTAL ASSETS:29,27751,2596,53411,22811,42310,766
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,7836,67815,6775,5902,241497
Accounts payable3,7005,41714,6774,5481,424345
Accrued liabilities831,2611,0001,042817152
Debt  1,263   
Other undisclosed current liabilities2,5344,5557146223,302367
Total current liabilities:6,31711,23317,6546,2125,543864
Noncurrent Liabilities
Long-term debt and lease obligation3,6184,5621,103   
Operating lease, liability3,6184,5621,103
Other undisclosed noncurrent liabilities(3,618)(4,562)    
Total noncurrent liabilities:3,6184,5621,103   
Total liabilities:9,93515,79518,7576,2125,543864
Commitments and contingencies 600    
Stockholders' equity
Stockholders' equity attributable to parent, including:19,34235,464(12,223)5,0165,8809,902
Common stock121211111111
Treasury stock, value(116)(116)    
Additional paid in capital192,990184,655105,04294,62085,94485,014
Accumulated deficit(173,544)(149,087)(117,276)(94,023)(80,075)(75,123)
Other undisclosed stockholders' equity attributable to parent   4,408  
Other undisclosed stockholders' equity (600)    
Total stockholders' equity:19,34234,864(12,223)5,0165,8809,902
TOTAL LIABILITIES AND EQUITY:29,27751,2596,53411,22811,42310,766

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Operating expenses(24,539)(31,684)(23,001)(14,063)(4,999)(5,083)
Operating loss:(24,539)(31,684)(23,001)(14,063)(4,999)(5,083)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes (127)(252)11547101
Loss from continuing operations before equity method investments, income taxes:(24,539)(31,811)(23,253)(13,948)(4,952)(4,982)
Other undisclosed income from continuing operations before income taxes82     
Net loss available to common stockholders, diluted:(24,457)(31,811)(23,253)(13,948)(4,952)(4,982)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(24,457)(31,811)(23,253)(13,948)(4,952)(4,982)
Comprehensive loss, net of tax, attributable to parent:(24,457)(31,811)(23,253)(13,948)(4,952)(4,982)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: